Press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Apr 22, 2021As part of its 2030+ sustainability goals, BD pledges carbon neutrality by 2040 across direct operations
In recognition of Earth Day, BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, reinforces its commitment to Advancing the world of health™ by affirming...
-
Apr 20, 2021
BD (Becton, Dickinson and Company), a leading global medical technology company, is voluntarily recalling specified lots of the ChloraPrep™ Hi-Lite Orange™ 26 mL Applicator (2% w/w...
-
Apr 20, 2021Company continues its commitment to expanding health care access through its long-standing support of UNICEF USA and their efforts to eliminate Maternal and Neonatal Tetanus
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a $1 million commitment over five years to UNICEF USA in support of UNICEF's work to...
-
Apr 14, 2021Clearance supported by clinical data from a feasibility study with favorable primary patency rates observed out to 180 days
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for...
-
Apr 13, 2021WHO Rapid Communication cites high accuracy for the detection of TB, rifampicin and isoniazid resistance on respiratory samples
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its BD MAX™ Molecular Multi-Drug Resistant Tuberculosis (MDR-TB) Assay was...
-
Apr 5, 2021
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will report its financial results for the second quarter of fiscal year 2021 on Thursday, May 6, 2021. BD will issue a press...
-
Apr 1, 2021
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it will invest $65 million to construct a state-of-the-art facility in Tucson, Arizona...
-
Apr 1, 2021BD Veritor™ Plus System supports return-to-school and return-to-work programs through serial testing
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization...
-
Mar 30, 2021
FRANKLIN LAKES, N.J. (March 30, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Brooke Story to the...
-
Mar 30, 2021New Test on the BD Veritor™ Plus System Can Detect SARS-CoV-2, Influenza A, Influenza B from Single Patient Sample
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA)...
-
Mar 24, 2021
BD (Becton, Dickinson and Company), a leading global medical technology company, has expanded a voluntary recall that was initiated on June 23, 2020 for specified catalog numbers of the...
-
Mar 17, 2021
FRANKLIN LAKES, N.J. (March 17, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement regarding the U.S....
-
Mar 9, 2021Reporting app helps facilitate SARS-CoV-2 testing and result reporting from BD Veritor™ Plus System
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced an agreement with ImageMover, a software platform that automates and simplifies medical...
-
Mar 4, 2021
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired GSL Solutions, Inc. ("GSL"), a privately-held company that develops...
-
Feb 22, 2021Aims to Pair BD Antigen Test with Scanwell Health Mobile App
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Scanwell Health, a leader in smartphone-enabled at-home medical tests, today announced a...
-
Feb 17, 2021
FRANKLIN LAKES, N.J. (Feb. 17, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the U.S. Food and Drug Administration’s...
-
Feb 12, 2021
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following upcoming virtual investor conferences: The...
-
Feb 12, 2021New single test for the BD MAX™ System also shows ability to detect U.K., South African Variants
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use...
-
Feb 8, 2021
FRANKLIN LAKES, N.J. (Feb. 8, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Dev Kurdikar, 52, to the...
-
Feb 4, 2021- First fiscal quarter revenues of $5.315 billion grew 25.8% on a reported basis. On a currency-neutral basis, revenues increased 24.3%.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $5.315 billion for the first fiscal quarter ended December 31,...
-
Feb 3, 2021In conjunction with clinical findings and the results of other laboratory testing, BD Multitest™ 6-Color TBNK Reagent with BD Trucount™ Tubes may help clinicians determine the risks of Intubation with Mechanical Ventilation and also of mortality in COVID-19 patients, aiding in patient management decisions
EYSINS, Switzerland, (Feb. 3, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the CE mark of BD Multitest™ 6-Color TBNK...
-
Feb 2, 2021- There is robust evidence that the BD vascular care solution and skin antiseptic for peripheral intravenous catheters used in the CLEAN3 randomized clinical trial can help improve patient outcomes
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that new clinical data have found robust evidence that using a vascular care solution...
-
Jan 26, 2021Polen to Succeed Vince Forlenza Effective April 28
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced Tom Polen, BD CEO and president, will assume additional responsibility as chairman of...
-
Jan 25, 2021
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.83 per common share, payable on March 31, 2021 to holders of record on March 10,...
-
Jan 25, 2021Peer-Reviewed Study Suggests BD Antigen Test Likely to Be More Selective at Detecting Patients Who Are Shedding Infectious SARS-CoV-2 Virus
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the publication of a peer-reviewed study that shows BD's antigen test may be more...
-
Jan 13, 2021The BD® AbSeq Immune Discovery Panel enables researchers to execute single cell experiments with high efficiency
FRANKLIN LAKES, N.J. (Jan. 13, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial release of the BD® AbSeq...
-
Jan 12, 2021- Preliminary first fiscal quarter 2021 revenues of $5.3 billion grew 25.6% on a reported basis. On a currency-neutral basis, revenues increased 24.2%, driven by higher base revenues in all three segments and COVID diagnostic revenues.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported, preliminary unaudited financial information for the first fiscal quarter ended Dec. 31,...
-
Jan 11, 2021Peer-reviewed clinical study published in the Journal of the Association for Vascular Access supports the use of midline catheters as an effective method for blood collection while reducing number of venipunctures
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the publication of the first-ever...
-
Dec 22, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the 39th Annual J.P. Morgan Healthcare Conference via webcast....
-
Dec 18, 2020BD earns certificate under Annex IX Chapter I & III
British Standards Institution (BSI), the national standards body for the United Kingdom and a designated European Notified Body, today announces it has certified its first group of products to the...
-
Dec 16, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received pandemic orders for needles and syringes totaling more than 1...
-
Dec 14, 2020
FRANKLIN LAKES, N.J. (Dec. 14, 2020) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today released its inaugural cybersecurity annual report,...
-
Dec 9, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced publication of the results from a 52-subject human clinical trial with the BD...
-
Dec 2, 2020Investment includes new manufacturing facility in Europe
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to invest approximately $1.2 billion over a 4-year period to expand and upgrade...
-
Nov 24, 2020
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.83 per common share, an increase of 5.1% from the previous quarter. The dividend...
-
Nov 23, 2020Reports Generated by BD Synapsys™ 3.84 Informatics Solution Simplify Mandatory Public Health Reporting
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new reporting capabilities for COVID-19 data, enabling scheduled reports to be...
-
Nov 19, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on...
-
Nov 12, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired the Medical Business assets of CUBEX LLC, which is a privately-held...
-
Nov 10, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor™ Plus...
-
Nov 9, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the following upcoming virtual healthcare conferences: Stifel...
-
Nov 9, 2020
FRANKLIN LAKES, N.J., Nov. 6, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Paddy O’Brien to worldwide...
-
Nov 9, 2020
FRANKLIN LAKES, N.J., Nov. 6, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the expanded role of Tony Ezell as president of...
-
Nov 5, 2020- Fiscal fourth quarter revenues of $4.784 billion grew 4.4% on a reported and currency-neutral basis.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.784 billion for the fourth fiscal quarter ended September 30,...
-
Nov 2, 2020The first shipment of 1.2 million SARS-CoV-2 Assays for use on the BD Veritor™ Plus System to be delivered in The Netherlands by mid-November
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the receipt of an order from the Dutch Ministry of Health for 9.2 million of its rapid,...
-
Oct 22, 2020Patrick Kaltenbach appointed chief technology officer
Dave Hickey promoted to president, Life Sciences segmentBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Patrick Kaltenbach as executive vice president and chief technology...
-
Oct 21, 2020
CerTest Biotec, along with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR...
-
Oct 16, 2020BD Multitest™ 6-Color TBNK Reagent with BD Trucount™ Tubes brings time-tested immune assessment solution to European clinicians treating COVID-19 patients
EYSINS, Switzerland, Oct. 16, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the CE mark and European availability of a...
-
Oct 7, 2020Global Mercy will deliver free, world-class surgical care to patients in African nations who lack healthcare access
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, this year celebrates its 25 year of philanthropic partnership with the global nonprofit, Mercy Ships,...
-
Oct 6, 2020Four of every ten women received inappropriate treatment
FRANKLIN LAKES, N.J., October 6, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the publication of an investigator-initiated study...
-
Oct 5, 2020BD FACSDuet™ Sample Preparation System, now available in the U.S., as the first fully automated sample-to-answer solution when integrated with the BD FACSLyric™ Flow Cytometer
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for...